Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities

After a complete clinical response to first-line therapy, surgically detected MRD on second-look laparoscopy (40/95, 42.1%) and ctDNA positivity (15/44, 34%) were each associated with shorter PFS and OS; SLL positivity was independently associated with OS (HR 4.40).

Clin Cancer ResPubMed 40748258DOI 10.1158/1078-0432.CCR-25-0512